Against a backdrop of exciting new developments in disease management, there is a need to improve access to innovation in Alzheimer’s Disease. At this year’s Alzheimer Europe Conference, Lilly and other leading experts called for urgent action to impro…
Chronic obstructive pulmonary disease (COPD) is straining Europe’s healthcare budgets, primarily through preventable hospitalizations. Early intervention is key to improve care, health outcomes and fiscal responsibility
Alzheimer’s disease is often diagnosed too late. A multi-national survey reveals barriers and points the way forward. Early diagnosis must become the standard to ensure patient’s meaningful interventions with the greatest impact. The time to act is now…
Europe’s flawed oversight of pesticides may be fueling a silent epidemic, warns Dutch neurologist Bas Bloem. His fight for reform pits him against industry, regulators — and time.
Inspired by the rare disease community’s passionate drive to advance policies that provide equitable access to care, UCB spearheaded Aspire4Rare: a global initiative supporting the development of rare disease policies.
Innovative solutions are driving change in the early diagnosis and intervention of cerebral palsy. Integrating AI into diagnostics and advancing research into neuroplasticity is finally engaging policymakers.
The post AI, new strategies could fast-trac…
Undetected Chronic Kidney Disease affects millions in Europe, but it could be preventable, manageable and tackled with the right policies.
As diabetes cases surge across Europe, healthcare systems are grappling with an escalation, leaving millions without sufficient access to early diagnosis, preventive care, and innovative treatments.
There is an urgent need to improve access to new innovations in the diagnosis and treatment of Alzheimer’s disease. Embracing breakthroughs such as blood-based biomarker testing, has the potential to transform timely, accurate diagnosis for the benefit…
In Czechia, over 160,000 people and approximately 4,000 children are living with rheumatoid arthritis. While modern medicine offers hope, early diagnosis and better access to treatment remain critical.
Lecanemab and donanemab are two of the most recent medicines to treat Alzheimer’s disease.
Governments, civil society and industry share views on the EU mandate we need to achieve the 2030 UNAIDS goals in Europe and beyond.
A recent European-wide patient survey study published in the European Journal of Human Genetics on Tuesday has uncovered significant delays in diagnosing rare diseases across the continent.
